Shire Sheds Dermagraft; Exits Regenerative Medicine
This article was originally published in The Pink Sheet Daily
Executive Summary
The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.